Stay updated on Ociperlimab Plus Tislelizumab vs Durvalumab in cCRT Clinical Trial
Sign up to get notified when there's something new on the Ociperlimab Plus Tislelizumab vs Durvalumab in cCRT Clinical Trial page.

Latest updates to the Ociperlimab Plus Tislelizumab vs Durvalumab in cCRT Clinical Trial page
- Check5 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check20 days agoChange Detected- Added a government operating-status notice and links, clarifying NIH Clinical Center operations and where to check updates. - Updated version from v3.1.0 to v3.2.0.SummaryDifference11%

- Check27 days agoChange Detected- Updated version from v3.0.2 to v3.1.0. - No other content changes detected.SummaryDifference0.3%

- Check41 days agoChange DetectedPage revision updated from v3.0.1 to v3.0.2, and the 'Back to Top' element was removed.SummaryDifference0.7%

- Check48 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.SummaryDifference0.7%

- Check55 days agoChange DetectedThe web page has undergone significant updates, including the addition of a facility name and location details, while removing specific state, country, and city information.SummaryDifference19%

- Check70 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.3%

Stay in the know with updates to Ociperlimab Plus Tislelizumab vs Durvalumab in cCRT Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ociperlimab Plus Tislelizumab vs Durvalumab in cCRT Clinical Trial page.